Patents
Literature
2 results about "Arterial Vasodilation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vasodilation directly affects the relationship between mean arterial pressure, cardiac output, and total peripheral resistance (TPR). Vasodilation occurs in the time phase of cardiac systole, whereas vasoconstriction follows in the opposite time phase of cardiac diastole.
Application of 4-chloro-3-ethylphenol in the preparation of drugs for preventing or treating ulcerative colitis and sepsis
ActiveCN119326738BAntibacterial agentsOrganic active ingredientsUlcerative colitisVascular endothelium
The present invention discloses the use of 4-chloro-3-ethylphenol in the preparation of drugs for preventing or treating ulcerative colitis and sepsis, and relates to the field of biomedical technology. It is experimentally confirmed in the present invention that the ryanodine receptor (RyRs) agonist 4-chloro-3-ethylphenol has significant effects in preventing or treating ulcerative colitis and sepsis, and 4-chloro-3-ethylphenol is a clinically potential drug for the preparation of drugs for preventing or treating ulcerative colitis and sepsis; meanwhile, using 4-chloro-3-ethylphenol as a reliable tool can clearly distinguish the two components of store-operated calcium channels (SOCE), that is, inducing ER / Ca<supgt;2+< / supgt; release through RyR, but blocking the entry of Ca<supgt;2+< / supgt; through SOC in vascular endothelial cells, having a dual effect; further experiments confirm that pure endothelial cell RyR / ER / Ca<supgt;2+< / supgt> release is a unique pathway for regulating EDH-mediated arterial vasodilation in a healthy state and has an anti-inflammatory effect on ulcerative colitis and sepsis.
Owner:QINGDAO UNIV
Use of acacetin or 6-hydroxyflavone in the preparation of anti-angina pectoris drugs
The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.
Owner:NANJING ANMAOHUA PHARM CO LTD